<DOC>
	<DOCNO>NCT01254279</DOCNO>
	<brief_summary>The purpose study allow patient similar evaluate TROPIC trial ( NCT00417079 ) , Investigators access cabazitaxel management metastatic Hormone Refractory Prostate Cancer ( mHRPC ) patient progress docetaxel document overall safety cabazitaxel patient . Please note country , patient recruitment end cabazitaxel become commercially available .</brief_summary>
	<brief_title>Early Access Cabazitaxel Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With Docetaxel-containing Regimen</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Inclusion criterion : Metastatic Hormone Refractory Prostate Cancer ( mHRPC ) previously treat docetaxelcontaining regimen Disease Progression docetaxelcontaining regimen mHRPC Surgical medical castration Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) : 02 Lifeexpectancy ≥3 month Adequate bone marrow , liver , renal function : Neutrophils &gt; 1500 /mm3 ; Hemoglobin &gt; 10 g/dL ; Platelets &gt; 100 x109/L ; Bilirubin &lt; ULN ; SGOT ( AST ) &lt; 1.5xULN ; SGPT ( ALT ) &lt; 1.5xULN ; Creatinine &lt; 1.5xULN . If creatinine 1.0 1.5 x ULN , creatinine clearance calculate accord CKDEPI formula patient creatinine clearance &lt; 60 mL/min exclude . Exclusion criterion : Prior radiotherapy ≥ 40 % bone marrow Prior radionuclide therapy ( samarium153 , strontium89 , P32… ) Prior surgery , radiation , chemotherapy , anticancer therapy within 4 week prior enrollment Active grade ≥2 peripheral neuropathy Active grade ≥2 stomatitis Active infection require systemic antibiotic antifungal medication Active cancer ( mHRPC ) include prior malignancy patient diseasefree ≤5 year ( except superficial basal cell skin cancer ) Known brain leptomeningeal involvement History severe hypersensitivity reaction ( ≥grade 3 ) docetaxel History severe hypersensitivity reaction ( ≥grade 3 ) polysorbate 80 contain drug History severe hypersensitivity reaction ( ≥grade 3 ) intolerance prednisone prednisolone Uncontrolled severe illness medical condition ( include uncontrolled cardiac arrhythmia , angina pectoris , hypertension diabetes mellitus ) . History congestive heart failure ( NYHA III IV ) myocardial infarction within last 6 month also allow . Concurrent plan treatment potent inhibitor inducers cytochrome P450 3A4/5 Participation clinical trial investigational drug Patient reproductive potential implementing accept effective method contraception The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>